Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Physiomics ( (GB:PYC) ).
Physiomics plc has secured a follow-on contract with a UK-based client to support a Phase 2 clinical study for a small molecule therapeutic targeting rheumatoid arthritis. The project, set to commence in 2027, underscores Physiomics’ commitment to providing valuable insights for the client’s clinical trial and expanding its project pipeline for the next financial year. The contract, valued between £116K and £169K, highlights the company’s strategic positioning in the biostatistics and data science industry.
Spark’s Take on GB:PYC Stock
According to Spark, TipRanks’ AI Analyst, GB:PYC is a Underperform.
Physiomics’ stock score is primarily impacted by significant financial instability, including declining revenues and negative profit margins. Technical indicators reinforce a bearish outlook. While recent corporate events suggest potential growth pathways, current valuation issues and financial challenges remain significant obstacles.
To see Spark’s full report on GB:PYC stock, click here.
More about Physiomics
Physiomics plc is a leading company in mathematical modelling, data science, and biostatistics, supporting the development of new therapeutics and personalized medicine solutions. They specialize in helping biotech and pharma companies streamline drug development through expertise in Modelling & Simulation, Biostatistics, Data Science, and Bioinformatics. Their proprietary Virtual Tumour technology and bespoke models have informed the development of over 100 commercial projects.
Average Trading Volume: 3,799,892
Technical Sentiment Signal: Sell
Current Market Cap: £803.5K
For an in-depth examination of PYC stock, go to TipRanks’ Overview page.